Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 136 to 150 of 284 results for coronavirus

  1. What is the effectiveness and safety of neutralising monoclonal antibodies against different SARS-CoV-2 variants?

    Outcome) P: people being treated for acute COVID-19 disease and who are not hospitalised with...

    Research recommendation
    Published
    9 March 2022

  2. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  3. Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (TA1002)

    Evidence-based recommendations on evinacumab (Evkeeza) for treating homozygous familial hypercholesterolaemia in people 12 years and over.

    Technology appraisal guidance
    Published
    11 September 2024
    View recommendations

    Sections for TA1002

  4. Diagnostics advisory committee members

    Biographies for all current members of the diagnostics advisory committee.

  5. What is the clinical effectiveness of D-dimer and other blood tests and clinical features as prognostic markers of developing post‑COVID‑19 syndrome?

    guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of...

    Research recommendation
    Published
    12 November 2021

  6. What symptoms do children, young people, pregnant women and older people with suspected post‑COVID‑19 syndrome present with?

    guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of...

    Research recommendation
    Published
    12 November 2021

  7. Acute coronary syndromes (NG185)

    This guideline covers the early and longer-term (rehabilitation) management of acute coronary syndromes. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina. The guideline aims to improve survival and quality of life for people who have a heart attack or unstable angina.

    NICE guideline
    Published
    18 November 2020
    View recommendations

    Sections for NG185

  8. Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating hormone-sensitive metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    7 July 2021
    View recommendations

    Sections for TA712

  9. Virtual ward platform technologies for acute respiratory infections: early value assessment (HTG697)

    Early value assessment (EVA) guidance on virtual ward platform technologies for acute respiratory infections.

    HealthTech guidance
    Published
    12 October 2023
    View recommendations

    Sections for HTG697

  10. What are the most clinically effective interventions (including social prescribing and structured community support) for managing post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Do any symptoms of post‑COVID‑19 syndrome predict the need for specialist intervention? Are there clusters of symptoms that identify response to interventions in post‑COVID‑19 syndrome? What is the clinical effectiveness of different service models of multimodality/multidisciplinary post‑COVID‑19 syndrome rehabilitation in improving patient‑reported outcomes (such as quality of life)? What is the clinical effectiveness of exercise interventions for people with post‑COVID‑19 syndrome? Does effectiveness vary for different population groups (for example sex, age, socioeconomic group, black, Asian and minority ethnic group communities or people with learning disabilities)? Does early exercise rehabilitation assist in improving symptoms of post‑COVID‑19 syndrome?

    guidance details Comes from guidance COVID-19 rapid guideline: managing the long-term effects of...

    Research recommendation
    Published
    12 November 2021

  11. Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)

    Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.

    Highly specialised technologies guidance
    Published
    19 April 2023
    View recommendations

    Sections for HST26

  12. Pulmonary artery pressure technologies for remote monitoring of chronic heart failure (HTG769)

    Evidence-based recommendation on the routine use of pulmonary artery pressure technologies for remote monitoring of chronic heart failure.

    HealthTech guidance
    Published
    5 February 2026
    View recommendations

    Sections for HTG769

  13. Standards framework for shared-decision-making support tools, including patient decision aids (ECD8)

    This document describes the framework for setting out a series of standards to support people using patient decision aids (PDAs) in assessing the usefulness and quality of a PDA. It will also be useful to those developing PDAs in enabling them to undertake a self-assessment of the quality of their tools and processes

  14. Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (TA898)

    Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    14 June 2023
    View recommendations

    Sections for TA898

  15. Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)

    Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.

    Technology appraisal guidance
    Published
    15 December 2021
    View recommendations

    Sections for TA752